Strategies to improve efficacy may include selecting patients based on the expression of immune-related biomarkers, and while predictive biomarkers for ICI response have not yet been established in NB, previous research in other solid tumors suggests that tumor mutational burden and PD-L1 expression may serve as reliable indicators [201]. This evidence concerns the gene CD274 and neoplasm.